K

K2 Medical Research | Tampa, FL

Research site

(Unclaimed)

Location

5130 Sunforest Drive Suite 110, Tampa, Florida, United States of America

Site insights

Top conditions

Top treatments

BHV-7000

SEP-363856

Buntanetap

ITI-1284

DT120

MK-1167-008

JNJ-64042056

MK-1167

MK-2214

MK-2214-004

Parent organization

This site is a part of K2 Medical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 12 total trials

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). A...

Enrolling

Early Alzheimer's Disease

Biological: MK-2214

Drug: Placebo

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depress...

Enrolling

Major Depressive Disorder

Other: Placebo

Drug: DT120

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in ba...

Enrolling

Treatment Resistant Depression

Device: Vagus Nerve Stimulation (VNS)

Locations recently updated

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease (Reτain)

The purpose of this study is to assess whether JNJ-64042056 affects the spread and build up of tau (a protein in brain) when compared with placebo, u...

Active, not recruiting

Alzheimer Disease

Drug: JNJ-64042056

Drug: Placebo

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with...

Enrolling

Generalized Anxiety Disorder

Drug: ITI-1284 10 mg

Drug: ITI-1284 20 mg